



Journal homepage: www.sciencearchives.org

ISSN: 2582-6697



Review Article

<http://dx.doi.org/10.47587/SA.2020.1104>



Cyanobacteria: an emerging source for antibacterial, antimycobacterial and antifungal properties

Abhishek Chauhan¹✉, Ritu Chauhan¹, Rupesh Kumar Basniwal² and Sachin C. Narwadiya³

¹Amity Institute of Environmental Toxicology, Safety and Management, Amity University, Sector-125, Noida, Uttar Pradesh, India

²Amity Institute for Advanced Research and Studies (M&D) Amity University, Sector-125, Noida, Uttar Pradesh, India

³Vigyan Prasar, Department of Science and Technology, Govt. of India, C-24, Qutub Institutional Area, New Delhi-110016
✉ akchauhan@amity.edu

Received Date: Feb 17, 2020 / Accepted Date: June 23, 2020 / Published Date: June 28, 2020

Abstract

Cyanobacteria are various group of gram-negative prokaryotes that originated before 3.5 billion years ago known as phototrophic blue green algae. This group is well known for their higher photosynthetic growth rate and capability to grow in adverse environmental conditions. Unique property of the algal group to grow in almost every environmental condition, makes them suitable candidate for the study of antimicrobial research. First time before 1500 BC, medicinal and nutritional properties have been investigated for *Nostoc* algal species to treat gout, fistula and cancer. In current scenario, less accessibility of life saving drugs, high cost of antibiotics and development of resistivity towards existing antibiotics, made it necessary to look forward for new research activities based on cyanobacteria and other plants for betterment of human society. The different extracts prepared from cultured cyanobacteria to isolate compounds are a common way to discover novel compounds. Most of the valuable cyanobacterial metabolites are concentrated in their biomass. For existence in nature, cyanobacteria secrete and contain various organic compounds. Compounds like proteins, fatty acids, vitamins, pigments, primary and secondary metabolites extracted from cyanobacteria are well known for different antimicrobial activities like antifungal, antiviral and antibacterial. Pharmaceutical companies have been shown commercial interest in this algal group due to presence of vast and diverse biological active compounds. In this review, we have shown panoramic view of cyanobacterial extracts and their commercial applications in different fields.

Keywords: Antibacterial, antimycobacterial and antifungal properties, cyanobacteria

Introduction

Cyanobacteria are the oxygenic, photosynthetic, gram-negative, oldest phototrophic organisms exhibited diverse biological activities. Approximately 2000 different strains of freshwater and marine cyanobacteria are found throughout world, which shows extraordinary ecological variety. Capability to grow in adverse condition and their autotrophic nature makes them eligible candidate to grow in low nutrient deficient lakes, ponds and oceans which pose serious threat for water and result into eutrophication (Chorus and Bartram, 1999; Duy et al., 2000). They are well known for different antimicrobial activity and being used for

production of various value-added products throughout the world. The first partly identified antimicrobial compound isolated from algae were obtained from unicellular green algae particularly, Chlorella which contained a substance termed as 'chlорellin' that exhibited inhibitory activity against Gram-positive and Gram-negative group of bacteria. In pharmaceutical companies especially in new drug discovery research division, last 40 years research is going on extraction of new compounds or drugs from cyanobacteria. Their development without supplement of organic substrate can be a practical advantage over the

Table 1: Antibacterial, antimycobacterial and antifungal properties of Cyanobacteria (from 1962 to 2019)

Cyanobacteria	Bacterial and Fungal species	References
<i>Lyngbya majuscule</i>	<i>Bacillus subtilis</i> , <i>Bacillus subtilis</i> , <i>Bacillus typhosus</i> , <i>Mycobacterium balnei</i> , <i>Mycobacterium phlei</i> , <i>Mycobacterium smegmatis</i> , <i>Sarcina lutea</i> , <i>Staphylococcus aureus</i> , <i>Candida albicans</i> , <i>Cryptococcus neoformans</i> , <i>Penicillium sp.</i>	Welch (1962); Gupta and Srivastava (1965); Moikha and Chu (1971)
<i>Oscillatoria princeps</i>	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , <i>Bacillus typhosus</i> , <i>E. coli</i>	Gupta and Srivastava, 1965
<i>Brachytrichia balani</i> , <i>Mastigocoleus testarum</i>	<i>Salmonella sp.</i> , <i>Staphylococcus aureus</i> , <i>Escherichia coli</i> , <i>Mycobacterium phlei</i> ,	Kobbia and Zaki, 1976
<i>Lyngbya majuscule</i>	<i>Mycobacterium smegmatis</i> , <i>Streptococcus pyogenes</i> , Compound identified: Malyngolide	Cardllina and Moore, 1979
<i>Oscillatoria sp. 1459/8</i> , <i>Oscillatoria redekei</i> , <i>Schizothrix sp. 1470/2</i> , <i>Synechococcus leopoliensis</i> , <i>Schizothrix sp. 1470/2</i> , <i>Synechococcus leopoliensis</i> , <i>Fischerella ambigua</i> , <i>Hapalosiphon hibernicus</i>	<i>Bacillus subtilis</i> , <i>Staphylococcus aureus</i> , <i>Aspergillus oryzae</i> , <i>Candida albicans</i> , <i>Penicillium notatum</i> , <i>Saccharomyces cerevisiae</i> , <i>Trichophyton mentagrophytes</i> . Compound identified: Ambiguines	Cannell et al., 1988
<i>Nostoc muscorum</i>	<i>Staphylococcus aureus</i> , <i>Pseudomonas aeruginosa</i> <i>Candida albicans</i> , <i>Cunninghamella blakesleeana</i> , <i>Rhizoctonia solani</i> , <i>Sclerotinia sclerotiorum</i>	De Cano et al. (1990), Bloor and England (1989)
<i>Scytonema sp.</i>	<i>S. cerevisiae</i> , <i>C. albicans</i> , <i>A. oryzae</i> , <i>P. notatum</i> , Compound identified: Tolytoxin and 6-Hydroxy-7-O-Methylscytophycline	Carmeli et al., 1990
<i>Tolythothrix tijpanensis</i>	<i>Aspergillus oryzae</i> , <i>Candida albicans</i> , <i>Trichophyton mentagrophytes</i>	Bonjouklian et al., 1991
<i>Westiellopsis prolifica</i>	<i>C. albicans</i> , <i>A. oryzae</i> , <i>Saccharomyces cerevisiae</i> , <i>Trichophyton mentagrophytes</i> , <i>Penicillium notatum</i> Compound identified: Ambiguines	Smitka et al, 1992
<i>Fischerella ambigua 108a</i>	<i>Bacillus subtilis</i> , <i>Micrococcus luteus</i> , <i>Escherichia coli</i> . Compound identified: Ambigol A & B	Falch et al., 1993 & 1995
<i>Phormedium sp. HS-273</i>	<i>Staphylococcus aureus</i>	Ohta et al., 1993
<i>Phormidium sp.</i> , <i>Mastigocladius laminosus</i> , <i>Mastigocladius laminosus</i>	<i>Staphylococcus aureus</i> , <i>Bacillus cereus</i> , <i>B. coagulans</i> , <i>B. licheniformis</i> , <i>B. sphaericus</i> , <i>B. subtilis</i> , <i>Streptococcus faecalis</i> , <i>S. viridi</i> , <i>E. coli</i> , <i>Proteus vulgaris</i> , <i>P. morganii</i> , <i>Pseudomonas denitrificans</i> , <i>Candida albicans</i>	Fish and Codd, 1994
<i>Scytonema lyngbyoides</i> , <i>Anabaena plantonica 115b</i> , <i>Pseudoanabaena catenata U7</i> , <i>Nostoc sp. 51</i> , <i>Nostoc commune NC1</i> , <i>Oscillatoria rubescens R19</i>	<i>Bacillus subtilis</i> , <i>Micrococcus luteus</i> , <i>Escherichia coli</i> , <i>Penicillium oxalicum</i>	Falch et al., 1995

<i>Aphanizomenon flos-aquae</i> , <i>Anabaena lemmermannii</i> , <i>Microcystis aeruginosa</i>	<i>Bacillus subtilis</i> , <i>Bacillus cereus</i> , <i>Escherichia coli</i>	Stensvik et al., 1998
<i>Nostoc commune</i>	<i>Aspergillus candidus</i> Compound identified: Nostofungicidine	Kajiyama et al., 1998
<i>Nostoc muscorum 1453/12a</i>	<i>Bacillus subtilis</i>	Cannell et al., 1988
<i>Tychonema bourrellyi</i>	<i>Bacillus subtilis</i> , <i>Bacillus cereus</i> , <i>Escherichia coli</i>	Stensvik et al., 1998
<i>Oscillatoria rubescens</i>	<i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , <i>Micrococcus flavus</i>	Kreitlow et al., 1999
<i>Nostoc commune 259</i>	<i>Staphylococcus epidermidis</i>	Jaki et al., 1999
<i>Limnothrix sp.</i>	<i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , <i>Micrococcus flavus</i> .	Kreitlow et al., 1999
<i>Fischerella ambigua 108b</i>	<i>Bacillus cereus</i> , <i>Staphylococcus epidermidis</i> , <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> , <i>Micrococcus luteus</i> .	Jaki et al., 1999
<i>Anabaena sp.</i> , <i>A. solitaria</i>	<i>Micrococcus flavus</i> and <i>Bacillus subtilis</i>	Kreitlow et al., 1999
<i>Lyngbya majuscule</i>	<i>Candida albicans</i> . Compound identified: Tanikolide	Singh et al., 1999
<i>Lyngbya majuscule</i>	<i>Candida albicans</i> compound identified: Tanikolide	Singh et al., 1999
<i>Langbya sp. 91/50</i> , <i>Langbya sp. 163</i> , <i>Langbya sp. 164</i> ,	<i>Bacillus cereus</i> , <i>Escherichia coli</i> , <i>Staphylococcus epidermidis</i>	Jaki et al., 1999
<i>Limnothrix sp.</i>	<i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , <i>Micrococcus flavus</i> .	Kreitlow et al., 1999
<i>Langbya sp. 91/50</i> , <i>Langbya sp. 163</i> , <i>Langbya sp. 164</i> , <i>Nostoc commune 122b</i> , <i>Nostoc commune 123b</i> , <i>Nostoc commune 124b</i> , <i>Tolypothrix distorta 153a</i> , <i>Tolypothrix distorta 96c</i> , <i>Scytonema myochrous 200b</i> , <i>Symploca muscorum 176</i> , <i>Tolypothrix byssoides 195</i> , <i>Phormidium sp. 178</i> , <i>Phormidium sp. 211</i>	<i>Bacillus cereus</i> , <i>Staphylococcus epidermidis</i> , <i>Candida albicans</i>	Jaki et al., 1999
<i>Anabaena variabilis 1</i>	<i>Bacillus subtilis</i> , <i>Chaetomium globosum</i> ,	Mundt et al., 2001; Kellam et al., 1988
<i>Gloeocapsa caldariorum 127</i> , <i>Calothrix gracilis 96</i> , <i>Limnothrix redekei HUB 052</i> <i>Limnothrix redekei HUB 052</i> , <i>Nostoc species 104</i> , <i>Oscillatoria species 234</i> , <i>Pseudoanabaena catenata</i>	<i>Bacillus subtilis</i>	Mundt et al., 2001
<i>Tolypothrix byssoides</i> (EAWAG195)	<i>Candida albicans</i> . Compound identified: Tolybyssidin A (1) Tolybyssidin B (2)	Jaki et al., 2001

<i>Fischerella ambigua</i>	<i>Staphylococcus epidermidis, Candida krusei.</i> Compound identified: Parsiguine	Ghasemi et al., 2004
<i>Spirulina platensis</i>	<i>B. subtilis, S. faecalis, , S. aureus, E. aerogenes, , S. epidermidis, E. cloacae, P. aeruginosa, E. coli S. typhimurium, P. vulgaris, C. albicans</i> Compound Identified: Heptadecane	Ozdemir et al. 2004
<i>Fischerella ambigua FS2, Fischerella ambigua FS18, Hapalosiphon aureus FS3, Hapalosiphon brasiliensis FS6, Hapalosiphon fontinalis FS7, Fischerella ambigua FS2, Hapalosiphon hibernicus FS33, Nostoc linckia FS8, Nostoc muscorum FS13, Nostoc punctiforme FS5, Stigonema ocellatum FS23, FS 30 & FS 14</i>	<i>Staphylococcus epidermidis, Escherichia coli, Bacillus subtilis, , Candida kefyr., Candida kefyr., Salmonella typhi, Candida kefyr, Candida albicans, salmonella typhi</i>	Soltani et al., 2005
<i>Anabaena sp., Chrococcus sp., Oscillatoria sp.</i>	<i>Bacillus megaterium, Bacillus thuringiensis</i>	Katircioglu et al., 2006
<i>Fischerella sp.</i>	<i>E. aerogenes M. tuberculosis, S. typhi, S. aureus, P. aeruginosa, , E. coli.</i> Compound identified: Hapalindole	Asthana et al., 2006
<i>Spirulina platensis</i>	<i>E. coli, S. aureus, , P. aeruginosa, S. typhi and K. pneumonia</i>	Kaushik and Chauhan, 2008
<i>Nostoc commune</i>	<i>B. subtilis, B. cereus, B. pumilus, E. coli, S. aureus, P. aeruginosa, S. typhi and K. pneumonia</i>	Chauhan et al., 2008
<i>Lyngbya majuscula</i>	<i>S. epidermidis, B. subtilis, B. cereus, S. faecalis, E. coli, C. albicans</i>	Kaushik et al., 2009
<i>Anabaena variabilis</i>	<i>S. aureus, E. coli, P. aeruginosa, S. typhi and K. pneumonia</i>	Kaushik et al., 2009
<i>Phormedium sp.</i>	<i>B. cereus. B. subtilis, , S. epidermidis, S. faecalis, E. coli, C. albicans</i>	Garima et al., 2013
<i>Tolypothrix tenuis, Anabaena variabilis and Cylindrospermum sp</i>	<i>Bacillus subtilis, Pseudomonas aeruginosa</i>	Malathi, et al., 2014
<i>Lyngbya sp.</i>	<i>Escherichia coli and Pseudomonas aeruginosa,</i>	Sundaramanickam et al., 2015
<i>Microcystis aeruginosa</i>	<i>A. parasiticus, A. flavus, , A. westerdijikia, , A. ochraceus ITAL 14, A. carbonarius ITAL 204, A. steynii IBT LKN 23096, Penicillium verrucosum BFE 500, Fusarium verticillioides ITEM 10027, F. proliferatum MPVP 328.</i>	Marrez et al., 2016
<i>Synechococcus spp. PCC7942</i>	<i>S. aureus (NCIM 2099), Pseudomonas aeruginosa (NCIM 5029), Klebsiella pneumonia (NCIM 2957), Enterobacter aerogenes (NCIM 5139) and Escherichia coli (NCIM 2065)</i>	Fatima et al., 2017
<i>Oscillatoria sp.</i>	<i>S. aureus (MRSA) ATCC 25923 Gram-positive Methicillin-resistant, B. anthracis and P. aeruginosa</i>	Wijesekara et al., 2017

	(ATCC 25853) <i>E. coli</i> and <i>S. typhi</i> (ATCC 25922 and <i>C. tropicalis</i>	
<i>Nostoc linckia</i>	<i>Pseudomonas aeruginosa</i> <i>Bacillus subtilis</i> , and <i>Staphylococcus aureus</i> susp. <i>aureus</i> , and two tested fungal strains <i>Aspergillus niger</i> and <i>Candida albicans</i>	Vanlalveni et al., 2018
<i>Anabaena circinalis</i> , <i>Nostoc entophysum</i>	<i>Staphylococcus aureus</i> ATCC 25923 , <i>E. coli</i> O 157:H7 , <i>L. monocytogenes</i> , <i>Bacillus subtilis</i> ATCC 6633, <i>Pseudomonas aeruginosa</i> ATCC 27853, <i>Salmonella typhimurium</i> CCM 5445	Yücer et al., 2018
35 cyanobacterial extracts	<i>Bacillus subtilis</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus sanguinis</i> , <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> , <i>Candida friedricki</i> , <i>Fusarium oxysporum</i> , <i>Aspergillus fumigatus</i> , <i>Monographella cucumerina</i> , <i>Alternaria alternate</i>	Saurav et al., 2019

microorganisms. The benefit of microbes, which can be cultured, such as cyanobacteria, is that a sustainable amount of anticipated bioactive compounds can be attained, which is not always possible for a product derived from a microbe other than cyanobacteria. Blue Green algae promise greater opportunities with all relatively inexpensive and easier approaches against some expensive and technically complex methods presently in use for new drug discovery.

Antimicrobial potential of cyanobacteria

Culturable microorganisms for screening of novel pharmaceuticals are of paramount importance. Historically, actinomycetes have been the most prolific producers of metabolites with significant antimicrobial activities. According to Bradner, actinomycetes are most closely examined group of organisms and presently known for production of more than 95% antimicrobial compounds in primary screening (Bradner, 1980). They can be cultured in the laboratory with relative ease to provide a consistent source of biologically active secondary metabolites (Patterson et al., 1993). Screening of cyanobacteria for antimicrobial compounds with pharmaceutical value received more attention. The molecules isolated from several cyanobacteria have broad spectrum of potential including fungicides and algicides toxins, antibiotics (Browitzka, 1995) (Table 1). Random screening of cyanobacteria will continue play an important role in the drug discovery process for unforeseeable future.

Cyanobacteria as a source of antifungal compounds

Flavanoid type compounds, Fischerellin A, Phytoalexin, Tolytoxin, Laxaphycins, Ambiguines, Calophycin, Sctophytin and Laxaphycins have been isolated from *Oscillatoria*, *Scytonema pseudohofmanii*, and *Anabaena laxa* and from other cyanobacterial species also which supposed to have anticandidal and antibacterial activity (Frankmolle et al., 1992). (Table 1)

Cyanobacteria as a source of antibacterial compounds




Fig.1. Inhibition zone showed by different extracts of Cyanobacteria against *Staphylococcus aureus*

Kaushik and Chauhan (2008) have been reported the antibacterial activity of several species of cyanobacteria such as *Anabaena*, *Lyngbya*, *Calothrix*, *Spirulina*, *Nostoc*, *Hapalosiphone*, *Phormidium* and *Oscillatoria* etc. against both Gram-positive (*S. aureus*, *B. subtilis*, *B. cereus* etc.) as well as Gram-negative bacteria (*E. coli*, *P. aeruginosa*, *S. typhi* etc.). These organisms can be genetically modified by using different biotechnological techniques to produce biological active compounds like Bacteriocin, Ambigol A, Parsiguine, Hapalindole, Hormothamnin A etc. Garima et al. (2013) have evaluated *Phormidium* for its significant antibacterial and anticandidal activity. Various species of *Anabaena* were evaluated for their antimicrobial activity and for active extracts which further screened for presence of chemical constituents through HPTLC and UV-HPLC techniques (Kaushik et al., 2009a; Chauhan et al., 2010). They have been also examined *Nostoc commune* and *Lyngbya majuscula* for potent antimicrobial activity against clinically significant microorganisms and further analyzed

their methanolic extract through UV-HPLC and HPTLC analysis. (Table 1)

Cyanobacteria as a source of antimycobacterial compounds

This have been reported by Rao et al. in 2007 for different spp. of cyanobacteria viz. *Hapalosiphon* sp., *Anabaena* sp. *Lyngbya* sp., *Westeillopsis prolifica*, *Spirulina* sp. *Anabaena variabilis*, *Anabaena cylindrica*, *Oscillatoria* sp. and *Scytonema* sp. against various species of Mycobacteria (*Mycobacterium tuberculosis* ATCC 27294, *M.tuberculosis* MDR, *M.avium*, *M. intracellulare* and *M. aurum*. (Table 1)

Conclusion and future prospects

Cyanobacteria produce plenty potential antimicrobial agents which are useful for human as well as for animals' welfare. Worldwide attention is drawn towards micro-algae for their possible use in several therapeutic and other products. Keeping in view the applied applications, it has been concluded that now this area is exploring rapidly. The major challenge in front of the current world is to fight effectively against the new emerging diseases especially multiple drug resistant microbial infections and to discover new compounds for the welfare of mankind and society. Now mostly antibiotics are becoming useless due to development of multiple drug resistivities in pathogens. This is an alarming situation for human species. To overcome from this situation, continuous research in basic as well as applied filed necessary for discovery of new active drug compounds from cyanobacteria.

Conflict of Interest

Authors hereby declare no conflict of interest.

References

- Asthana, R.K., Srivastava, A., Singh, A.P., Deepali, Singh, S.P., Nath, G., Srivastava, R. and Srivastava, B.S. 2006. Identification of an antimicrobial entity from the cyanobacterium *Fischerella* sp. isolated from bark of *Azadirachta indica* (Neem) tree. *Journal of Applied Phycology*. 18, Number-1, 33-39.
- Bloor, S. and England, R.R. 1989. Antibiotic production by the cyanobacterium *Nostoc muscorum*. *Journal of Applied Phycology*. 1, 367-372.
- Bonjouklian, R., Smitka, T.A., Doolin, L.E., Molloy, R.M., Debono, M., Shaffer, S.A., Moore, R.E., Stewart, J.B. and Patterson, G.M.L. 1991. Tjipanazoles, new antifungal agent from the blue green alga *Tolyphothrix tjipanasensis*. *Tetrahedron*. 47, 7739-7750.
- Cannell, R.J.P., Owsianka, A.M. and Walker, J.M. 1988. Results of a Large-Scale Screening Programme to Detect Antibacterial Activity from Freshwater Algae. *Br. Phycol. J.* 23, 41-44.
- Cardellina, J.H., Moore, R.E., Arnold, E.V. and Clardy, J. 1979. Structure and absolute configuration of malyngolide, an antibiotic from the marine blue green alga *Lyngbya majuscula* Gomont. *J. Org. Chem.* 44, No-23, 4039-4042.
- Carmeli, S., Moore, R.E., and Patterson, G.M.L., Corbett, T.H., and Valerio, F.A. 1990 c. Tantazoles, unusual cytotoxic alkaloids from the blue-green alga *Scytonema mirabile*. *J. Am. Chem. Soc.* 112, 8195-8197.
- Carmeli, S., Moore, R.E. and Patterson, G.M.L. 1990 a. Isonitriles from the blue-green alga *Scytonema mirabile*. *J. Org. Chem.* 4431-8.
- Carmeli, S., Moore, R.E. and Patterson, G.M.L. 1990 b. Tolytoxin and New Scytophyccins from three species of *Scytonema*. *J. Nat. Prod.* 53, No-6, 1533-1542.
- Chorus, I. and Bartram, J. 1999. Toxic cyanobacteria in the water. E & F.N. Spon, London.
- De Cano, M.M.S., De Mule, M.Cr., De Caire, G.Z., and De Halperin, D.R. 1990. Inhibition of *Candida albicans* and *Staphylococcus aureus* by phenolic compounds from terrestrial cyanobacterium *Nostoc muscorum*. *Journal of Applied Phycology*. 2, No-1, 79-81.
- Duy, T.N., Lam, P.K., Shaw, G.R. and Connell, D.W. 2000. Toxicological and risk assessment of freshwater cyanobacterial (blue-green algae) toxin in water. *Rev. Environ. Contam. Toxicol.* 163, 113-185.
- Falch, B.S., Konig, G.M., Wright, A.D. and Sticher, O. 1993. Anbigol A and B: New Biologically Active polychlorinated Aromatic Compounds from the Terrestrial Blue-Green Alga *Fischerella ambigua*. *J. Org. chem.* 58, 6570-6575.
- Falch, B.S., Konig, G.M., Wright, A.D., Sticher, Angerhofer, C.K., Pezzuto, J.M. and Bachmann, H. 1995. Biological Activities of Cyanobacteria: Evaluation of Extracts and Pure Compounds. *Planta Med.* 61, 321-328.
- Fatima, N., Ahmad, I. Z., & Chaudhry, H. (2017). Alterations in the antibacterial potential of *Synechococcus* spp. PCC7942 under the influence of UV-B radiations on skin pathogens. *Saudi journal of biological sciences*, 24(7), 1657-1662.
- Fish, S.A. and Codd, G.A. 1994. Bioactive compound production by thermophilic and thermotolerant cyanobacteria (blue-green algae). *World J. Microbiol. Biotech.* 10, 338-341.
- Garima, Chauhan, A., Goyal, P., and Kaushik, P (2013) Antibacterial and anticandidal screening of extracellular and intracellular extracts of *Phormedium*, a cyanobacterium. *Int. J. Chem. And Life Sciences*, Vol. 2(3), 1107-1111.
- Ghasemi, Y., Yazdi, M.T., Shafiee, A., Amini, M., Shokravi, S. and Zarrini, G. 2004. Parsiguine, A Novel Antimicrobial substance from *Fischerella ambigua*. *Pharmceutical Biology*. 42, No-5, 318-322.
- Gupta, A.B. and Shrivastava, G.C. 1965. On Antibiotic properties of some fresh water algae. *Hydrobiologica*. 25, 285-288.
- Hunter, P.R. 1995. Cyanobacterial toxins and their potential risk to drinking water supplies. *Microbiol. Eur.* 3, 8-10.
- Jaki, B., Orjala, J., Burgi, H.R. and Sticher, O. 1999. Biological Screening of Cyanobacteria for Antimicrobial and Molluscicidal Activity, Brine Shrimp Lethality, and Cytotoxicity. *Phrmaceutical Biology*. 37, No. 2. 138-143.
- Jaki, B., Zerbe, O., Heilmann, J. and Sticher, O. 2001. Two Novel Cyclic Peptides with Antifungal Activity from the Cyanobacterium *Tolyphothrix byssidea* (EAWAG 195). *J. Nat. Prod.* 64, 154-158.

- Jones, G.J. and Korth, W. 1995. In situ production of volatile odor compounds by river and reservoir phytoplankton population in Australia. *Water Sci. Technol.* 31, 145-151.
- Katircioglu, H., Beyatli, Y., Aslim, B., Yuksekdag, Z. and Atici, T. 2006. Screening of antimicrobial Agent Production of Some Microalgae in Freshwater. *The internet Journal of Microbiology.* 2, No.-2, 1-9.
- Kaushik, P. 2000. Introductory Microbiology. Emkay Publications, Post Box 9410, B-19 East Krishna Nagar, Swami Dayanand Marg, Delhi. pp VIII+1-46.
- Kaushik, P. and Chauhan, A (2008) Antibacterial potential of aqueous and organic extracts of *N. commune* a cyanobacterium. *VEGETOS (An International Journal of Plant Sciences).* Vol. 21, NO.1.77-80.
- Kaushik, P. and Chauhan, A (2008) In vitro antibacterial activity of laboratory grown culture of *Spirulina platensis*. *Indian Journal of Microbiology.* Vol. 48. No. 3, 348-352.
- Kaushik, P., Chauhan, A., Garima, and Goyal P (2009) Antibacterial Potential and UV-HPLC Analysis of Laboratory-Grown Culture of *Anabaena variabilis*. *Internet Journal of Food Safety,* Vol.11, 2009, p. 11-18.
- Kaushik, P., Garima, Chauhan, A., and Goyal P (2009) Screening of *Lyngbya majuscula* for potential antimicrobial activity and HPTLC analysis of active methanolic extract. *Journal of Pure and Applied Microbiology*, Vol.3, No. 1, 169-174.
- Kellam, S.J., Cannell, R.J.P., Owsianka, A.M., and Walker, J.M. 1988. Results of large-scale screening programme to detect antifungal activity from marine and fresh water microalgae in laboratory culture. *Brit. Phycol J.* 23, 45-47.
- Kobbia, I.A. and Zaki, D. 1976. Biological evaluation of algal filtrates. *Planta Med.* 30, 90-92.
- Kreitlow, S., Mundt, S. and Lindequist, U. 1999. Cyanobacteria-a potential source of new biologically active substances. *Journal of Biotechnology.* 70, 61-63.
- Malathi, T., Babu, M. R., Mounika, T., Snehalatha, D., & Rao, B. D. (2014). Screening of cyanobacterial strains for antibacterial activity. *Phykos*, 44(2), 6-11.
- Marrez, D. A., & Sultan, Y. Y. (2016). Antifungal activity of the cyanobacterium *Microcystis aeruginosa* against mycotoxicogenic fungi. *Journal of Applied Pharmaceutical Science*, 6(11), 191-198.
- Moikeha, S.N and Chu, G.W. 1971. Dermatitis-producing alfa *Lyngbya majuscula* Gomont in Hawaii. II. Biological properties of the toxic factor. *Journal of Phycology.* 7, 8-13.
- Mundt, S., kreitlow, S., Nowotny, A. and Effmert, U. 2001. Biological and pharmacological investigation of selected cyanobacteria. *Int. J. Hyg. Environ. Health.* 203, 327-334.
- Ohta, S., Chang, T., Ikegami, N., Kondo, M. and Miyata, H. 1993. Antibiotic substance produced by a newly isolated marine microalga, *Chlorococcum HS-101*. *Bull. Environ. Contam. Toxicol.* 50, 171-178.
- Ozdemir, G., Karabay, N.U., Dalay, M.C. and Pzarbasi, B. 2004. Antibacterial activity of volatile component and Various Extracts of *Spirulina platensis*. *Phytother. Res.* 18, 754-757.
- Saurav, K., Macho, M., Kust, A., Delawská, K., Hájek, J., & Hrouzek, P. (2019). Antimicrobial activity and bioactive profiling of heterocytous cyanobacterial strains using MS/MS-based molecular networking. *Folia microbiologica*, 64(5), 645-654.
- Singh, I.P., Milligan, K.E. and Gerwick, W.H. 1999. Tanikolide, a toxic and antifungal lactone from the marine Cyanobacterium *Lyngbya majuscula*. *J. Nat. Prod.* 62, 1333-1335.
- Smitka, T.A., Bonjouklian, R., Doolin, L., Jones, N.D., Deeter, J.B., Yoshida, W.Y., Prinsep, M.R., Moore, R.E. and Patterson, G.M.L. 1992. Ambiguine isonitriles, fungicidal halapindole-type alkaloids from three genera of blue-green algae belonging to the Stigonemataceae. *J. Org. Chem.* 57, 857-861.
- Soltani, N., Khavari-Nejad, R.A., Yazdi, M.T., Shokrevi, S., Fernandez-valiente, E. 2005. Screening of Soil Cyanobacteria for Antifungal and Antibacterial Activity. *Pharmaceutical Biology.* 43, 455-459.
- Stensvik, Skulberg, O.M., Underdal, B. and Hormazabal, V. 1998. Antibacterial properties of extracts from selected planktonic freshwater cyanobacteria-a comparative study of bacterial bioassays. *The Society for Applied Microbiology.* 84, 1117-1124.
- Sundaramickam, A., Palanivel, S., Shekhar, S., Kumaresan, S., & Balasubramanian, T. (2015). In vitro evaluation of Antimicrobial activity of some selected Cyanobacterial extracts against human pathogens. *IJAPBC*, 4(1), 36-43.
- Vanlalveni, C., Rajkumari, K., Biswas, A., Adhikari, P. P., Lalfakzuala, R., & Rokhum, L. (2018). Green synthesis of silver nanoparticles using *Nostoc linckia* and its antimicrobial activity: a novel biological approach. *BioNanoScience*, 8(2), 624-631.
- Welch, A.M. 1962. Preliminary survey of fungistatic properties of marine algae. *J. Bacteriol.* 83, 97-99.
- Welch, A.M. 1962. Preliminary survey of fungistatic properties of marine algae. *J. Bacteriol.* 83, 97-99.
- Wijesekara, W. A. M. A., & Manage, P. M. (2017). In vitro screening of, antibacterial antifungal and cytotoxicity activities in crude extract of freshwater cyanobacterium *Oscillatoria* sp. *Journal of Tropical Forestry and Environment*, 7(2).
- Yücer, T. D., Beyatlı, Y., & Pabuçcu, K. (2018). The antiproliferative and antimicrobial effects of cultivated *Anabaena circinalis* Rabenhorts ex Bornet and Flahault and *Nostoc entophysum* Bornet and Flahault. *Tropical Journal of Pharmaceutical Research*, 17(8), 1571-1577.

How to cite this article:

Chauhan, A., Chauhan, R. Basniwal, R.K., Narwadia, S.C. (2020) Cyanobacteria: an emerging source for antibacterial, antimycobacterial and antifungal properties *Science Archives*, 1 (1), 35-41 DOI: <http://dx.doi.org/10.47587/SA.2020.1104>

This work is licensed under a [Creative Commons Attribution 4.0 International License](#).

